InterstitialomaNCT07337980
A Study on the Safety and Effectiveness of Endoscopic Intracavitary Submucosal Dissection for Gastric Extracavitary-Type Submucosal Tumors
An observational study of Interstitialoma and Endoscopic Surgery, run by Zhongda Hospital.
Trial summary
The aim of this study is to explore the safety and efficacy of endoscopic surgery in the treatment of extraluminal growing stromal tumors Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Interstitialoma, Endoscopic Surgery
- What is being tested?
- Extraluminal growing stromal tumors treated endoscopically
- Type of treatment
- Surgery or procedure
- How many people
- 20 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2026to 31 Dec 2026
- How long will I take part?
- 12 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with gastric stromal tumor with extraluminal growth
Who may be able to join
- (1) CT scan showed extramural protrusion of the stomach (2) ultrasonic endoscopy revealed submucosal tumors with extra-gastric growth; (3) patients received ESD/EFTR or surgical treatment
Who cannot join
- (1) patients had malignant tumors in the stomach or had undergone stomach surgery (2) follow-up records were incomplete.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The aim of this study is to explore the safety and efficacy of endoscopic surgery in the treatment of extraluminal growing stromal tumors
Read the detailed description
The aim of this study is to explore the safety and efficacy of endoscopic surgery in the treatment of extraluminal growing stromal tumors
- Conditions
- Interstitialoma, Endoscopic Surgery
- Being tested
- Extraluminal growing stromal tumors treated endoscopically
- Keywords
- endoscopic surgery, interstitialoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Extraluminal growing stromal tumors treated endoscopicallyProcedure or surgery
To observe the safety and efficacy of endoscopic treatment of extraluminal growing stromal tumors
| Study group | Role | What they receive |
|---|---|---|
| Endoscopic-surgery Group | Patients with extraluminal growing stromal tumors undergoing endoscopic treatment Receives: Procedure: Extraluminal growing stromal tumors treated endoscopically |
What is being measured
The primary outcome is the main question the study is designed to answer.
Complete resection rate
Complete resection rate of extraluminal growing stromal tumors
Measured: 12 months
Secondary outcomes (1)
Recurrence-free survival
Recurrence-free survival of extraluminal growing stromal tumors after surgery
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Jan 2026
- Study start1 Jan 2026 (estimated)
- Primary completion12 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for InterstitialomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20 participants (estimated)
- Target duration
- 12 Months
Sponsor and investigators
- Lead sponsor
- Zhongda Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ruihua Shi, Zhongda Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07337980
- Sponsor's protocol ID
- GI of Zhongda Hospital
- Status last verified
- Jan 2026
- First submitted
- 3 Jan 2026
- Last updated
- 13 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Since this data may involve the privacy of patients, hospital ethics should be followed.
Study at a glance
From the registry record, last updated by the sponsor on 13 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Study on the Safety and Effectiveness of Endoscopic Intracavitary Submucosal Dissection for Gastric Extracavitary-Type Submucosal Tumors
- ClinicalTrials.gov ID
- NCT07337980
- Acronym / sponsor ID
- GI of Zhongda Hospital
- Conditions
- Interstitialoma, Endoscopic Surgery
- Keywords
- endoscopic surgery, interstitialoma
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Zhongda HospitalUniversity, hospital or other
- Study start
- 1 Jan 2026 (estimated)
- Primary completion
- 12 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 13 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to explore the safety and efficacy of endoscopic surgery in the treatment of extraluminal growing stromal tumors
Detailed description
The aim of this study is to explore the safety and efficacy of endoscopic surgery in the treatment of extraluminal growing stromal tumors
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 12 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Endoscopic-surgery Group | – | Procedure: Extraluminal growing stromal tumors treated endoscopicallyPatients with extraluminal growing stromal tumors undergoing endoscopic treatment |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with gastric stromal tumor with extraluminal growth
Key inclusion criteria (1 listed)
- (1) CT scan showed extramural protrusion of the stomach (2) ultrasonic endoscopy revealed submucosal tumors with extra-gastric growth; (3) patients received ESD/EFTR or surgical treatment
Key exclusion criteria (1 listed)
- (1) patients had malignant tumors in the stomach or had undergone stomach surgery (2) follow-up records were incomplete.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Extraluminal growing stromal tumors treated endoscopicallyTo observe the safety and efficacy of endoscopic treatment of extraluminal growing stromal tumors | Procedure or surgery | Endoscopic-surgery Group |
Primary outcome
Complete resection rate
Time frame: 12 months
Complete resection rate of extraluminal growing stromal tumors
1 secondary outcome
Recurrence-free survival
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jan 2026.
- Individual participant dataSharing planned: Undecided. Since this data may involve the privacy of patients, hospital ethics should be followed.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of Interstitialoma and Endoscopic Surgery, run by Zhongda Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 13 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ruihua Shi, Ph.D (13951799326, ruihuashi@126.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complete resection rate (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jan 2026.